

## **Embargo**

The ASBMR is sensitive to issues of commercial confidentiality and relevant aspects of the U.S. Securities and Exchange (SEC) regulations. Therefore, the ASBMR reminds all readers that everyone must adhere to the SEC regulations and treat all scientific information as confidential until the embargo has been lifted. The embargo lifts at the start time of the session in which the presentation is being made. Any reader of, or listener to, ASBMR 2019 Annual Meeting content may be viewed as an “insider” by the SEC due to knowledge of information included in abstracts, particularly clinical trial abstracts. SEC regulations may call for criminal penalties for using such information.

**Abstracts submitted to the ASBMR 2019 Annual Meeting are embargoed – that is, unavailable for public release in written, oral or electronic communications – until the start time of the session in which the presentation is being made at the ASBMR Annual Meeting.** Public release includes presentation of data by the presenting author, colleagues, or others (1) in writing, on the internet or in other electronic formats, (2) orally in interviews or at other sessions/meetings that are not part of this official ASBMR program and/or take place before the embargo is lifted, (3) at the ASBMR 2019 Annual Meeting before the embargo is lifted and (4) in traditional text publications (e.g. journals, newspapers, newsletters) that will be published before the embargo is lifted. In addition, ASBMR reminds presenters and attendees that other organizations’ and entities’ embargoes should be honored. Any issues that arise in relation to this policy should be promptly reported to the ASBMR Executive Director in writing. This is a longstanding ASBMR policy that will be enforced.